Michael Barbella, Managing Editor09.20.22
PerkinElmer Inc. has appointed Max Krakowiak as senior vice president and chief financial officer (CFO), replacing Jamey Mock, who left the company to pursue an outside opportunity. Krakowiak was the company’s vice president of corporate finance, and has served in financial leadership roles of increasing responsibility for the last four years.
“I would like to thank Jamey for the significant impact he’s had on making PerkinElmer’s goals come to fruition the past several years,” said Prahlad Singh, president and CEO, PerkinElmer, Inc. “His financial and strategic expertise have helped accelerate the Company’s evolution as a leading life sciences innovator. While I will sincerely miss Jamey, I wish him all the best as he continues to have a significant impact on the advancement of global health in his new role. I am pleased to appoint Max as CFO. I have worked closely with him over the last four years as he has played an integral role on the finance leadership team and was a key project leader in our divestiture. I am confident in Max’s future contributions as we move ahead in an exciting new chapter for the company.”
Krakowiak had served as PerkinElmer’s finance chief of staff, focusing on driving global finance transformation through people, process and automation. He brings experience across global financial planning and analysis, commercial finance and business development. Prior to PerkinElmer, Krakowiak worked for GE in various corporate audit leadership roles.
“Reflecting on my time at PerkinElmer, I am extremely proud to have been part of a talented team that was able to accomplish such a significant transformation of both our portfolio and financial profile, ” said Mock. “I look forward to following the company’s future successes, and I know that Max will bring valuable expertise as he steps into the role.”
PerkinElmer is a global provider of end-to-end solutions that help scientists, researchers, and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, its team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. The company reported approximately $5 billion in 2021 revenues and serves customers in 190 countries.
“I would like to thank Jamey for the significant impact he’s had on making PerkinElmer’s goals come to fruition the past several years,” said Prahlad Singh, president and CEO, PerkinElmer, Inc. “His financial and strategic expertise have helped accelerate the Company’s evolution as a leading life sciences innovator. While I will sincerely miss Jamey, I wish him all the best as he continues to have a significant impact on the advancement of global health in his new role. I am pleased to appoint Max as CFO. I have worked closely with him over the last four years as he has played an integral role on the finance leadership team and was a key project leader in our divestiture. I am confident in Max’s future contributions as we move ahead in an exciting new chapter for the company.”
Krakowiak had served as PerkinElmer’s finance chief of staff, focusing on driving global finance transformation through people, process and automation. He brings experience across global financial planning and analysis, commercial finance and business development. Prior to PerkinElmer, Krakowiak worked for GE in various corporate audit leadership roles.
“Reflecting on my time at PerkinElmer, I am extremely proud to have been part of a talented team that was able to accomplish such a significant transformation of both our portfolio and financial profile, ” said Mock. “I look forward to following the company’s future successes, and I know that Max will bring valuable expertise as he steps into the role.”
PerkinElmer is a global provider of end-to-end solutions that help scientists, researchers, and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, its team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. The company reported approximately $5 billion in 2021 revenues and serves customers in 190 countries.